Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81441-inherited-bone-marrow-failure-multi-gene-panel
    Ask Trek AI about this page

    CPT 81441: Genetic Panel for Inherited Bone Marrow Failure Syndromes

    Commercial payers pay $2366 on average nationally for this procedure.

    CPT code 81441 describes a targeted genomic sequence analysis panel for inherited bone marrow failure syndromes that analyzes a blood specimen for at least 30 genes to detect germline mutations associated with disorders such as Fanconi anemia; service type: molecular diagnostic targeted gene panel, typical site of service: clinical laboratory or pathology laboratory with physician interpretation.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 81441 policy alerts

    Get alerted when payer policies referencing 81441 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    For CPT 81441, Blue Cross Blue Shield and Cigna show wider commercial rate dispersion while Aetna and BUCA are tighter. Calculating the interquartile ranges (P75 minus P25) yields: Blue Cross Blue Shield $1,167.00 ( $3,019.90 - $1,852.90 ), Cigna $1,676.40 ( $2,958.00 - $1,281.60 ), UnitedHealth Group $1,469.10 ( $2,938.20 - $1,469.10 ), Aetna $742.00 ( $2,039.00 - $1,297.00 ), and BUCA $1,231.40 ( $2,832.50 - $1,601.10 ). These differences indicate Cigna and Blue Cross Blue Shield have the widest spread, while Aetna exhibits the tightest interquartile range.

    Average commercial pricing centered on BUCA at a mean of $2,365.80 provides a midpoint against which individual payers vary: Aetna’s mean is $1,641.90, UnitedHealth Group’s mean is $2,422.40, Cigna’s mean is $2,332.30, and Blue Cross Blue Shield’s mean is $2,599.50. Minimum and maximum extremes are notable for several payers (for example, Blue Cross Blue Shield max $8,709.40 and Aetna min $372.10), underscoring that outlier contracts can push realized reimbursements well beyond interquartile spreads.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 12-year-old patient with progressive pancytopenia and a family history notable for Fanconi anemia is referred to a pediatric hematology-oncology clinic. Peripheral blood is collected and sent to a molecular diagnostics laboratory for a comprehensive targeted genomic panel that evaluates at least 30 genes associated with inherited bone marrow failure syndromes. The clinical workflow begins with the hematologist ordering the test using CPT 81441, documenting clinical history (cytopenias, dysmorphic features, family history), and attaching prior bone marrow aspirate and cytogenetic results. The laboratory receives the blood specimen, performs DNA extraction, next-generation sequencing of the gene panel, bioinformatic variant calling and annotation, and issues a clinical report describing pathogenic, likely pathogenic, and variants of uncertain significance relevant to IBMFS. Results are routed back to the ordering hematologist/oncologist who integrates molecular findings with clinical and family history to guide genetic counseling, surveillance, and possible family testing. Typical site of service is an outpatient clinic or hospital-affiliated outpatient laboratory; the service type is molecular pathology / genomic testing performed by clinical molecular diagnostics or anatomic pathology laboratory with oncology and pathology oversight.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    88342Immunohistochemistry, per specimen

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207ZP0102X
    207L00000X
    207RI0200X
    364SP1700X
    224ZF0002X
    251300000X
    183700000X
    225C00000X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    C18.9Malignant neoplasm of colon, unspecified
    C25.9Malignant neoplasm of pancreas, unspecified
    C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung
    C50.919Malignant neoplasm of unspecified site of unspecified female breast
    C61Malignant neoplasm of prostate
    C92.10Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
    C95.10Chronic leukemia of unspecified cell type not having achieved remission
    D46.9Myelodysplastic syndrome, unspecified
    D47.1Chronic myeloproliferative disease
    D47.9Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified

    Showing 1–10 of 29

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Performed on tissue specimens when immunophenotyping or protein expression is needed alongside genetic testing for differential diagnosis.

    88341 | Immunohistochemistry, each additional single antibody stain | Additional IHC stains that may complement molecular results in marrow or tissue evaluation.

    81235 | EGFR gene analysis, common variants | Single-gene targeted analysis for therapeutic or diagnostic purposes; may be ordered separately for specific mutation testing outside a broad panel.

    81445 | Targeted genomic sequence analysis panel, 5-50 genes | Smaller targeted panels that overlap with 81441 gene content; used when fewer genes are interrogated or as reflex testing.